



US008109918B2

(12) **United States Patent**
Eaton et al.

(10) **Patent No.:** **US 8,109,918 B2**
(45) **Date of Patent:** ***Feb. 7, 2012**

(54) **SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS**

(75) Inventors: **Donald J. Eaton**, Los Altos, CA (US);
Mary L. Moran, Woodside, CA (US);
Rodney Brenneman, San Juan
Capistrano, CA (US)

(73) Assignee: **Intersect ENT, Inc.**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

5,035,706 A	7/1991	Giantureo et al.
5,116,311 A	5/1992	Löfstedt
5,139,832 A	8/1992	Hayashi et al.
5,189,110 A	2/1993	Ikematu et al.
5,246,455 A	9/1993	Shikani
5,342,296 A	8/1994	Persson et al.
5,443,498 A	8/1995	Fontaine
5,507,807 A	4/1996	Shippert
5,512,055 A	4/1996	Domb et al.
5,538,738 A	7/1996	Ritter et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 101 05 592 A1 8/2002

(Continued)

OTHER PUBLICATIONS

Final Office Action mailed on Jan. 8, 2009, for U.S. Appl. No. 10/800,162, filed Mar. 12, 2004, 5 pages.

(Continued)

(21) Appl. No.: **12/479,794**

(22) Filed: **Jun. 6, 2009**

(65) **Prior Publication Data**

US 2009/0238859 A1 Sep. 24, 2009

Related U.S. Application Data

(62) Division of application No. 10/800,162, filed on Mar. 12, 2004, now Pat. No. 7,544,192.

(60) Provisional application No. 60/454,918, filed on Mar. 14, 2003.

(51) **Int. Cl.**
A61M 31/00 (2006.01)

(52) **U.S. Cl.** **604/514**; 604/506

(58) **Field of Classification Search** 604/93.01,
604/891.1, 890.1, 57, 59-64, 510, 514, 506;
128/204.12; 424/434; 606/196

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,580,568 A	4/1986	Gianturco
4,737,141 A	4/1988	Spits
4,753,636 A	6/1988	Free

Primary Examiner — Kevin C Sirmons

Assistant Examiner — Catherine N Witczak

(74) *Attorney, Agent, or Firm* — Morrison & Foerster LLP

(57) **ABSTRACT**

The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.

17 Claims, 2 Drawing Sheets

